Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

The company has just picked up a new approval for targeted cancer drug Rozlytrek(entrectinib), a rival to Bayer’s Vitrakvi (larotrectinib), and for anti-CD79b antibody drug conjugate Polivy (polatuzumab

Roche undercuts price of Bayer cancer drug after winning FDA approval

Vitrakvi, which Bayer acquired from Loxo Oncology, won approval in patients with NTRK gene fusions in November. ... Roche could derail Bayer’s progress, however, in part because of its willingness to compete on price.

Bayer takes control of BlueRock stem cell joint venture

Deal values BlueRock at $1bn. Bayer is buying out private equity partner Versant Ventures and founders in its cell therapy joint venture BlueRock Therapeutics for $240m, three years after setting up ... In addition to the $240m buyout fee, Bayer has also

Transgene slumps as viral cancer therapy fails phase 3 trial

Pexa-Vec (pexastimogene devacirepvec) – one of the new class of oncolytic virus therapies (OVT) – didn’t add to the efficacy of therapy when it was added to treatment with

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]